Sona Nanotech signs Chile trial partner for targeted hyperthermia...
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan talked with Proactive about the company’s latest step in advancing its targeted hyperthermia therapy (THT) towards market approval. Speaking from a major biotech conference in Boston, Regan shared …